Umthengisi we-Empagliflozin CAS:864070-44-0

I-Empagliflozin sisithinteli esitsha, esinamandla nesikhethayo se-SGLT-2, siphucula ulawulo lwe-glycemic kunye neempawu ze-metabolic syndrome kwiigundane ezineswekile. I-Empagliflozin (igama lorhwebo elithi Jardiance) sisithinteli se-sodium glucose co-transporter-2 (SGLT-2), kwaye ibangela ukuba iswekile egazini ikhutshwe zizintso kwaye ikhutshwe kumchamo. I-Empagliflozin inokubangela ukuphelelwa ngamanzi emzimbeni kwaye ikhokelele ekunciphiseni uxinzelelo lwegazi, okubangela ukuba izigulana zibe nesiyezi okanye ziphelelwe ngamandla kwaye zingasebenzi kakuhle kwezintso. Umngcipheko wezigulana ezindala, ingakumbi ezo zingasebenzi kakuhle kwezintso kunye ne-diuretics, ubonakala umkhulu. I-FDA ifuna ukuba uBoehring no-Eli Lilly benze izifundo ezine emva kokuthengisa: uvavanyo olupheleleyo lweziphumo zentliziyo oluqhubekayo, uvavanyo lwe-pharmacokinetics yabantwana kunye ne-pharmacodynamics, uvavanyo lokhuseleko lwabantwana kunye nokusebenza kakuhle, uvavanyo lobuthi beyeza (ingakumbi impembelelo yomsebenzi wezintso, amathambo kunye nokukhula kunye nophuhliso).